A Study of of HOT1030 in Patients With Advanced Solid Tumors
NCT ID: NCT05060263
Last Updated: 2021-09-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
42 participants
INTERVENTIONAL
2021-03-12
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of HB0030 Injection in Patients With Advanced Solid Tumors
NCT05706207
A Study of Injection HB0025 in Patients With Advanced Solid Tumors
NCT04678908
Phase I Study of HS-20108 in Participants With Advanced Solid Tumors
NCT06936735
A Study of HS-20110 in Participants With Advanced Solid Tumors
NCT06892379
Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
NCT05701709
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
HOT-1030
HOT-1030 is a Recombinant Humanized CD137 Monoclonal Antibody Injection
Cohort 2
HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
HOT-1030
HOT-1030 is a Recombinant Humanized CD137 Monoclonal Antibody Injection
Cohort 3
HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
HOT-1030
HOT-1030 is a Recombinant Humanized CD137 Monoclonal Antibody Injection
Cohort 4
HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
HOT-1030
HOT-1030 is a Recombinant Humanized CD137 Monoclonal Antibody Injection
Cohort 5
HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
HOT-1030
HOT-1030 is a Recombinant Humanized CD137 Monoclonal Antibody Injection
Cohort 6
HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
HOT-1030
HOT-1030 is a Recombinant Humanized CD137 Monoclonal Antibody Injection
Cohort 7
HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
HOT-1030
HOT-1030 is a Recombinant Humanized CD137 Monoclonal Antibody Injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HOT-1030
HOT-1030 is a Recombinant Humanized CD137 Monoclonal Antibody Injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Willing and able to provide signed and dated informed consent prior to any study-related procedures and willing and able to comply with all study procedures.
3. Patients with histologically or cytologically confirmed advanced malignant solid tumor who have received or been intolerant of all standard therapies thought to confer clinical benefit.
4. Measurable disease on imaging base on RECIST v1.1 for solid tumors;
5. Stop anticancer therapy for more than 5 half-lives or 4 weeks (whichever is shorter) prior to study entry;
6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
7. Adequate organ function, as indicated by the laboratory values.
8. Female patients of childbearing potential must have a negative serum pregnancy test at screening; Male patients and the female patients of childbearing potential must agree to use highly effective contraceptive measures throughout the study starting with the Screening Visit through 90 days after the last dose of study treatment is received.
9. Life expectancy \>3 months.
Exclusion Criteria
2. Active primary CNS tumor or metastatic CNS tumor (expect the patients who had received the treatment and stopped the treatment for more than 4 weeks before first dose), active epilepsy, Spinal cord compression or Cancerous meningitis.
3. Active autoimmune disease or history of autoimmune disease requiring systemic therapy \< 2 years prior to screening except hypothyroidism, vitiligo, Grave's disease, Hashimoto's disease, or Type I diabetes. Patients with childhood asthma or atopy that has not been active in the 2 years prior to study screening are eligible.
4. Require systematic anti-infective therapy a week before first dose because of active infection.
5. Taken the surgical operations not related to the research 4 weeks before first dose
6. Used of systemic corticosteroids (a dose equivalent \> 10 mg/day of prednisone or )or other immunosuppressive agents, excepted:
1. Patients are allowed to have topical use or inhaled glucocorticoid.
2. Patients are allowed to have a less than seven-day glucocorticoid treatment preventing or treat non-autoimmune allergic diseases.
7. The toxicity of previous anti-tumor therapy has not recovered (defined as not recovering to grade 0 or 1, except for alopecia) or has not fully recovered from previous surgery.
8. During the 6 months prior to screening, the patient had a history of major cardiovascular and cerebrovascular events, such as myocardial infarction, coronary angioplasty or bypass surgery, heart valve repair, unstable arrhythmias, unstable angina, transient ischemic attack, or cerebrovascular accidents.
9. New York Heart Association (NYHA) grade III or IV congestive heart failure.
10. Patients with uncontrolled hypertension (systolic blood pressure ≥160mmHg or diastolic blood pressure ≥100mmHg at the time of screening) who had been on a stable dose of antihypertensive drugs for at least 4 weeks at the time of screening).
11. Active hepatitis B (hepatitis B virus titer \>103 copies /ml or 200IU/ml); Hepatitis C virus infection (HCV-RNA above the detection limit); Prophylaxis antiviral therapy other than interferon is allowed. In patients with advanced liver cancer (HCC), hepatitis B virus titer \>104 copies /ml or 2000IU/ml should be excluded.
12. A history of known congenital and acquired immunodeficiency, including positive HIV antibody tests.
13. Patients with a known history of severe allergic reactions to macromolecular protein formulations/monoclonal antibodies or to any investigational drug component (CTCAE V5.0 grade greater than 3).
14. Participated in clinical trials of other drugs within 4 weeks before the first administration.
15. Pregnant or lactating women or women at risk of pregnancy have a positive pregnancy test before the first medication.
16. Other investigators consider that the patient has any clinical or laboratory abnormality that makes him unsuitable for participation in this clinical study.
17. prior history of a clear neurological or psychiatric disorder, including epilepsy or dementia.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Huabo Biopharm Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Han Baohui, Doctor
Role: PRINCIPAL_INVESTIGATOR
Shanghai Chest Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Huaota Biopharmaceutical Co., Ltd.
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HOT-1030-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.